- Home
- GLTO vs DSS Comparison
GLTO vs DSS Comparison
Compare GLTO & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- DSS
- Stock Information
- Founded
- GLTO 2011
- DSS 1984
- Country
- GLTO Denmark
- DSS United States
- Employees
- GLTO N/A
- DSS N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- DSS Containers/Packaging
- Sector
- GLTO Health Care
- DSS Consumer Discretionary
- Exchange
- GLTO Nasdaq
- DSS Nasdaq
- Market Cap
- GLTO 9.5M
- DSS 9.1M
- IPO Year
- GLTO 2020
- DSS N/A
- Fundamental
- Price
- GLTO $5.81
- DSS $1.02
- Analyst Decision
- GLTO Buy
- DSS
- Analyst Count
- GLTO 1
- DSS 0
- Target Price
- GLTO $10.00
- DSS N/A
- AVG Volume (30 Days)
- GLTO 16.5K
- DSS 20.9K
- Earning Date
- GLTO 11-01-2024
- DSS 11-13-2024
- Dividend Yield
- GLTO N/A
- DSS N/A
- EPS Growth
- GLTO N/A
- DSS N/A
- EPS
- GLTO N/A
- DSS N/A
- Revenue
- GLTO N/A
- DSS $25,019,000.00
- Revenue This Year
- GLTO N/A
- DSS N/A
- Revenue Next Year
- GLTO N/A
- DSS N/A
- P/E Ratio
- GLTO N/A
- DSS N/A
- Revenue Growth
- GLTO N/A
- DSS N/A
- 52 Week Low
- GLTO $5.62
- DSS $1.00
- 52 Week High
- GLTO $23.50
- DSS $3.46
- Technical
- Relative Strength Index (RSI)
- GLTO 25.82
- DSS 29.23
- Support Level
- GLTO $5.62
- DSS $1.05
- Resistance Level
- GLTO $6.94
- DSS $1.11
- Average True Range (ATR)
- GLTO 0.34
- DSS 0.07
- MACD
- GLTO 0.02
- DSS -0.02
- Stochastic Oscillator
- GLTO 11.27
- DSS 4.81
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.